Molecular basis of host-pathogen interaction in septic shock

Current Opinion in Microbiology

Volumn 1, Issue 1, 1998, Pages 49-55

  Heumann, Didier ^a   Glauser, Michel P ^a   Calandra, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NEGIBACTERIA; POSIBACTERIA;

CD14 ANTIGEN; LIPOPOLYSACCHARIDE; PEPTIDOGLYCAN;

ANIMAL; BACTERIAL INFECTION; BACTERIUM; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; MICROBIOLOGY; REVIEW; SEPTIC SHOCK;

ANIMALS; ANTIGENS, CD14; BACTERIA; BACTERIAL INFECTIONS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; PEPTIDOGLYCAN; SHOCK, SEPTIC;

EID: 0031987912     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(98)80142-2     Document Type: Article

References (77)

1. Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer PH, Wagner H: T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med 1992, 175:91-98.
2. Schlievert PM, Bohach GA, Ohlendorf DH, Stauffacher CV, Leung DYM, Murray DL, Earhart CA, Jablonski ML: Molecular structure of Staphylococcus and Streptococcus superantigens. J Clin Immunol 1995, 15:4S-10S.
3. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990, 249:1431-1433.
4. Pugin J, Heumann D, Tomasz A, Kravchenko V, Akamatsu Y, Nishijima M, Glauser MP, Tobias P, Ulevitch RJ: CD14 is a pattern recognition receptor. Immunity 1994, 1:509-516.
5. Ulevitch RJ, Tobias P: Recognition of endotoxin by cells leading to transmembrane signaling. Curr Biol 1994, 6:125-130.
6. Heumann D, Gallay P, Barras C, Zaech P, Ulevitch RJ, Tobias PS, Glauser MP, Baumgatner JD: Control of LPS binding and LPS-induced TNF secretion in human peripheral blood monocytes. J Immunol 1992, 148:3505-3512.
7. Wright SD, Levin SM, Jong MTC, Chad Z, Kabbash LG: CR3 (CD11b/CD18) expresses one binding site for Arg-Gly-Asp containing peptides and a second site for bacterial lipopolysaccharide. J Exp Med 1989, 169:175-183.
8. Ingalls RR, Golenbock DT: CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med 1995, 181:1473-1479.
9. Wurfel MM, Hailman E, Wright SD: Soluble CD14 acts as a shuttle in the neutralization of lipopolysacchride (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 1995, 181:1743-1754.
10. Yu B, Hailman E, Wright SD: Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest 1997, 99:315-324. The authors show that lipopolysaccharide (LPS)-binding protein (LBP) and soluble CD14 shuttle not only LPS, but also phospholipids. Phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine are each transferred by LBP from membranes to high density lipoprotein.
11. Park CT, Wright SD: Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins. J Biol Chem 1996, 271:18054-18060. Lipopolysaccharide-binding protein (LBP) was found associated in plasma with lipoprotein particles (11.4 + 0.12nm in diameter) together with apoA-I and factor-H-related proteins. The important message is that apparently all plasma LBP is associated with these particles.
12. Wurfel MM, Wright SD: Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers. Preferential interaction with particular classes of lipid. J Immunol 1997, 158:3925-3934. This paper provides evidence that the phospholipid component of high density lipoprotein (HDL), phosphorylcholine, is both necessary and sufficient for lipopolysaccharide-binding protein (LBP)-catalyzed neutralization of lipoloysaccharide by HDL.
13. Yu B, Wright SD: Catalytic properties of lipopolysacharide (LPS) binding protein. J Biol Chem 1996, 271:4100-4105. The authors report on the kinetics of the interactions between lipopolysaccharide (LPS), LPS-binding protein (LBP) and soluble CD14. LBP interacts simultaneously with both a LPS micelle and soluble CD14 during transfer of an LPS monomer to the soluble CD14. LBP-catalyzed transfer is first order with respect to soluble CD14 and LPS concentration, and the apparent Km values are 1-2 μg/ml for soluble CD14 and 100 μg/ml for LPS. These values are within the range of physiological concentrations for soluble CD14 and LPS.
14. Gallay P, Heumann D, Le Roy D, Barras C, Glauser MP: Mode of action of anti- lipopolysaccharide binding protein (LBP) antibodies for prevention of endotoxemic shock in mice. Proc Natl Acad Sci USA 1994, 91:7922-7926.
15. Haziot A, Ferrero E, Köntgen F, Hijiya N, Yamamoto S, Sliver J, Stewart CL, Goyert SM: Resistance to endotoxin shock and reduced dissemination of Gram-negative bacteria in CD14-deficient mice. Immunity 1996, 4:407-414. The role of CD14 in bacterially induced and LPS-induced shock was tested in CD14-deficient mice produced by gene targeting in embryonic stem cells. CD14-deficient mice were found to be highly resistant to shock induced by LPS and bacteria. However, at very high doses of LPS or bacteria, mice died through CD14-independent mechanisms. This report illustrates the dose-dependent role of LPS with regard to CD14, and indicates that, at physiological doses of LPS, CD14 plays a crucial role.
16. ••]). LBP knockout mice were found to be resistant to a low dose challenge of LPS. Furthermore, in these mice peritonitis due to Salmonella typhimurium was lethal whereas heterozygous mice survived. Survival was associated with a decreased number of bacteria. This suggests that LBP could play a benefical role in infection contributing to phagocytosis processes.
17. Bazil V, Strominger JL: Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol 1991, 147:1567-1574.
18. Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, Busse LA, Zukowski MM, Wright SD: Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 1994, 179:269-277.
19. Vita N, Lefort S, Sozzani P, Richards S, Borysiewicz LK, Ferrara P, Labéta MO: Detection and biochemical characteristics of the receptor for complexes of soluble CD14 and bacterial lipopolysaccharide. J Immunol 1997, 158:3457-3462.
20. Hedlund M, Svensson M, Nilsson A, Duan RD, Svanborg C: Role of ceramide-signaling pathway in cytokine responses to P-fimbriated Escherichia coli. J Exp Med 1996, 183:1037-1044.
21. Mattsson E, Rollof J, Verhoef J, van Dick H, Fleer A: Serum-induced potentiation of tumor necrosis factor alpha production by human monocytes in response to staphylococcal peptidoglycan: involvement of different serum factors. Infect Immun 1994, 62:3837-3843.
22. Timmerman CP, Mattsson E, Martinez-Martinez L, de Graaf L, Van Strijp JAG, Verbrugh HA, Verhoef J, Fleer A: Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun 1993, 61:4167-4172.
23. Weidemann B, Brade H, Rietschel ET, Dziarski R, Bazil V, Kusumoto S, Flad HD, Ulmer AJ: Soluble peptidoglycan-induced monokine production can be blocked by anti- CD14 monoclonal antibodies and by Lipid A partial structures. Infect Immun 1994, 62:4709-4715.
24. Cauwels A, Wan E, Leismann M, Tuomanen E: Coexistence of CD14-dependent and independent pathways for stimulation of human monocytes by Gram-positive bacteria. Infect Immun 1997, 65:3255-3260.
25. Heumann D, Barras C, de Jonge B, Severin A, Glauser MP, Tomasz A: Gram positive cell walls stimulate the synthesis of TNF alpha and IL-6 by human monocytes. Infect Immun 1994, 62:2715-2721.
26. Weidemann B, Schletter J, Dziarski R, Kusumoto S, Stetler F, Rietschel ET, Flad HD, Ulmer AJ: Specific binding of soluble peptidoglycan and muramyldipeptide to CD14 on human monocytes. Infect Immun 1997, 65:858-864. This is the first report showing direct binding of a microbial product other than LPS (soluble peptidoglycan, in this study) to CD14. All other studies in the field were performed using indirect evidence with blocking anti-CD14 antibodies.
27. Cleveland MG, Gorham JD, Murphy TL, Tuomanen E, Murphy KM: Lipoteichoic acid preparations of Gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. Infect Immun 1996, 64:1906-1912.
28. Dokter WHA, Dijkstra AJ, Koopmans SB, Stulp BK, Keck W, Halle MR, Vellenga E: G(Anh)M Tetra, a natural bacterial cell wall breakdown product, induces interleukin-1 beta and interleukin-6 expression in human monocytes. J Biol Chem 1994, 269:4201-4206.
29. Cavaillon JM, Marie C, Caroff M, Ledur A, Godard I, Poulain D, Fitting C, Haeffner-Cavaillon N: CD14/LPS receptor exhibits lectin-like properties. J Endotoxin Res 1997, 3:471-480.
30. Krziwon C, Zähringer U, Kawahara K, Weidemann B, Kusumoto S, Rietschel ET, Flad HD, Ulmer AJ: Glycosphingolipids from Sphingomonas paucimobilis induce monokine production in human mononuclear cells. Infect Immun 1995, 63:2899-2905.
31. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988, 81:1162-1172.
32. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Wett S, Warren RS, Starnes HF, et al.: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 1987, 7:1942-1951.
33. Smith JW, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Scharfman WH, Miller LL, Fenton RG, Conlon KC, et al.: The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992, 10:1141-1152.
34. Beasley D, Schwartz JH, Brenner BM: Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 1991, 87:602-608.
35. Thijs LG, Hack CE: Time course of cytokine levels in sepsis. Intensive Care Med 1995, 21:S16-S21.
36. Heumann D, Glauser MP: Anticytokine strategies for the treatment of septic shock: relevance of animal models. Curr Top Microbiol Immunol 1996, 216:299-311.
37. Burroughs M, Prasad S, Cabellos C, Mendelman PM, Tuomanen E: The biological activities of peptidoglycan in experimental Haemophilus influenzae meningitis. J Infect Dis 1993, 167:464-468.
38. Spellerberg B, Prasad S, Cabellos C, Burroughs M, Cahill P, Tuomanen E: Penetration of the blood-brain barrier: enhancement of drug delivery and imaging by bacterial glycopeptides. J Exp Med 1995, 182:1037-1044.
39. Galdiero F, Cipollaro de I'Ero G, Benedetto N, Galdiero M, Tufano MA: Release of cytokines induced by Salmonella typhimurium porins. Infect Immun 1993, 61:155-161.
40. Tufano MA, Rossano F, Catalanotti P, Liguori G, Capasso C, Ceccarelli MT, Marinelli P: Immunobiological activities of Helicobacter pylori porins. Infect Immun 1994, 62:1392-1399.
41. Ma Y, Weis JJ: Borrelia burgdorferi outer surface lipoproteins OspA and OspB possess B-cell mitogenic and cytokine-stimulatory properties. Infect Immun 1993, 61:3843-3853.
42. Tai KF, Ma Y, Weis JJ: Normal human B lymphocytes and mononuclear cells respond to the mitogenic and cytokine-stimulatory activities of Borrelia burgdorferi and its lipoprotein OspA. Infect Immun 1994, 62:520-528.
43. Reddi K, Wilson M, Poole S, Meghji S, Henderson B: Relative cytokine-stimulating activities of surface components of the oral periodontopathogenic bacterium Actinobacillus actinomycetemcomitans. Cytokine 1995, 7:534-541.
44. Mangan DF, Wahl SM, Sultzer BM, Mergenhagen SE: Stimulation of human monocytes by endotoxin-associated protein: inhibition of programmed cell death (apoptosis) and potential significance in adjuvancity. Infect Immun 1992, 60:1684-1686.
45. Heeg K, Miethke T, Wagner H: Superantigen-mediated lethal shock: the functional state of ligand-reactive T cells. Curr Top Microbiol Immunol 1996, 216:83-100.
46. Bhakdi S, Klonisch T, Nuber P, Fischer W: Stimulation of monokine production by lipoteichoic acids. Infect Immun 1991, 59:4614-4620.
47. Keller R, Fischer W, Keist R, Bassetti S: Macrophage response to bacteria: induction of marked secretory and cellular activities by lipoteichoic acids. Infect Immun 1992, 60:3664-3672.
48. Standiford TJ, Arenberg DA, Danforth JM, Kunkel SL, VanOttern GM, Strieter RM: Lipoteichoic acid induces secretion of interleukin-8 from human blood monocytes: a cellular and molecular analysis. Infect Immun 1994, 62:119-125.
49. Roach TIA, Barton CH, Chatterje D, Blackwell JM: Macrophage activation: lipoarabinomannan from avirulent and virulent strains of Mycobacterium tuberculosis differentially induces the early c-fos, KC, JE, and tumor necrosis factor-α. J Immunol 1993, 150:1886-1896.
50. Adams LB, Fukutomi Y, Krahenbuhl JL: Regulation of murine macrophage effector functions by lipoarabinomannan from mycobacterial strains with different degrees of virulence. Infect Immun 1993, 61:4173-4181.
51. Dahl KE, Shiratsuchi H, Hamilton BD, Ellner JJ, Toosi Z: Selective induction of transforming growth factor β in human monocytes by lipoarabinomannan of Mycobacterium tuberculosis. Infect Immun 1996, 64:399-405.
52. Dockrell HM, Young SK, Britton K, Brennan PJ, Rivoire B, Waters MFR, Lucas SB, Shahid F, Dojki M, Chiang TJ et al.: Induction of Th 1 cytokine responses by mycobacterial antigens in leprosy. Infect Immun 1996, 64:4385-4389.
53. Barnes PF, Chatterje D, Brennan PJ, Rea TH, Modlin RL: Tumor necrosis factor production in patients with leprosy. Infect Immun 1992, 60:1441-1446.
54. Vecchiarelli A, Puliti M, Torosantucci A, Cassone A, Bistoni F: In vitro production of tumor necrosis factor by murine splenic macrophages stimulated with mannoprotein constituents of Candida albicans cell wall. Cell Immunol 1991, 134:65-76.
55. Ausiello CM, Urbani F, Gessani S, Spagnoli GC, Gomez MJ, Cassone A: Cytokine gene expression in human peripheral blood mononuclear cells stimulated by mannoprotein constituents from Candida albicans. Infect Immun 1993, 61:4105-4111.
56. Castro M, Ralston NVC, Morgenthaler TI, Rohrbach MS, Limper AH: Candida albicans stimulates arachidonic acid liberation from alveolar macrophages through α-mannan and β-glucan cell wall components. Infect Immun 1994, 62:3138-3145.
57. Hoffman OA, Standing JE, Limper AH: Pneumocystis carinii stimulates tumor necrosis factor-α release from alveolar macrophages through a β-glucan-mediated mechanism. J Immunol 1993, 150:3932-3940.
58. Ingalls RR, Arnaout MA, Golenbock DT: Ouside-in signaling by lipopolysaccharide through a tailless integrin. J Immunol 1997, 159:433-438. The authors have expressed either a full-length CR3 or a mutated form deficient in the cytoplasmic domain in fibroblastic CHO cells. They showed that full-length CR3 was necessary to produce phagocytic signals. In contrast, lipopolysaccharide (LPS) activation did not require the cytoplasmic domain. In fact, LPS activation through CD14 or CR3 of cells occurs without the obligatory participation of a transmembrane receptor.
59. Lei MG, Morrison DC: Lipopolysaccharide/Lipid A receptors on lymphocytes and macrophages. Int Rev Immunol 1990, 6:223-235.
60. Schletter J, Brade H, Brade L, Krüger C, Loppnow H, Kusumoto S, Rietschel ET, Flad HD, Ulmer AJ: Binding of lipopolysaccharide (LPS) to an 80-kilodalton membrane protein of human cells is mediated by soluble CD14 and LPS-binding protein. Infect Immun 1995, 63:2576-2580.
61. Zhang Y, Doerfler M, Lee TC, Guillemin B, Rom WN: Mechanisms of stimulation of interleukin-1b and tumor necrosis factor-α by Mycobacterium tuberculosis components. J Clin Invest 1993, 91:2076-2083.
62. Soell M, Lett E, Holveck F, Schöller M, Wachsmann D, Klein JP: Activation of human monocytes by streptococcal rhamnose glucose polymers is mediated by CD14 antigen, and mannan binding protein inhibits TNF-α release. J Immunol 1995, 154:851-860.
63. Jahr TG, Ryan L, Sundan A, Lichenstein HS, Skjak-Braek G, Espevik T: Induction of tumor necrosis factor production from monocytes stimulated with mannuronic acid polymers and involvement of lipopolysaccharide-binding protein, CD14, and bactericidal/permeability-increasing factor. Infect Immun 1997, 65:89-94.
64. Otterlei M, Varum KM, Ryan L, Espevik T: Characterization of binding and TNF-α inducing ability of chitosans on monocytes: the involvement of CD14. Vaccine 1994, 12:825-832.
65. Espevik T, Otterlei M, Skjak-Braek G, Ryan L, Wright SD, Sundan A: The involvement of CD14 in stimulation of cytokine production by uronic acid polymers. Eur J Immunol 1993, 23:255-261.
66. Hmama Z, Mey A, Normier G, Binz H, Revillard JP: CD14 and CD11b mediate serum-independent binding to human monocytes of an acylpolygalactoside isolated from Klebsiella pneumoniae. Infect Immun 1994, 62:1520-1527.
67. Kusunoki T, Wright SD: Chemical characteristics of Staphylococcus aureus molecules that have CD14-dependent stimulating activity. J Immunol 1996, 157:5112-5117.
68. Fisher CJ, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RMH, Panacek EA, Vincent JL, et al.: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993, 21:318327
69. Abraham E, Wunderick R, Sliverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995, 273:934-941.
70. Cohen J, Carlet J, The INTERSEPT Study Group: INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996, 24:1431-1440.
71. Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Wilats S, Bouza C, krausch D, et al. Assessment of the safety and efficacy of the monoclonal antitumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996, 24:733-742.
72. Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierobe L, Stephens S, Ney UM: CDP571, a humanized antibody to human tumor necrosis factor-a: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 1995, 23:1461-1469.
73. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RHM, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996, 334:1697-1702.
74. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, et al.: p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 1997, 277:1531-1538.
75. Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994, 271:1836-1843.
76. Opal SM, Fisher CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997, 25:1115-1124.
77. Tapping RI, Tobias PS: Cellular binding of soluble CD14 requires lipopolysaccharide (LPS) and LPS-binding protein. J Biol Chem 1997, 272:23157-23164. LPS-binding protein (LBP) is traditionally known to function as a catalyst in the transfer of LPS to soluble CD14 (Yu & Wright, 1996 [13]). The data presented in this paper reveals that LBP is actually a physical part of the soluble CD14-containing cell-associated complexes. Cellular binding of soluble CD14 is dependant on LBP and LPS. Once bound, soluble CD14 is internalized suggesting a novel general mechanism by which non myeloid cells clear LPS.